Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm.
Salisbury RA, Curto-Garcia N, O'Sullivan J, Chen F, Polzella P, Godfrey AL, Russell J, Knapper S, Willan J, Frewin R, Joshi S, Arami S, Burns S, Teh CH, Wadelin F, Dhanapal J, Neelakantan P, Milojkovic D, Psaila B, Szydlo R, Francis S, Cargo C, Jain M, McGregor A, Wallis L, Duncombe A, Hussein H, Dyer P, Munro L, Bond L, McMullin MF, Somervaille TCP, Garg M, Sekhar M, Harrison C, Mead AJ, Innes AJ. Salisbury RA, et al. Among authors: milojkovic d. Leukemia. 2021 Aug;35(8):2424-2430. doi: 10.1038/s41375-021-01143-2. Epub 2021 Feb 12. Leukemia. 2021. PMID: 33580204 Free PMC article. No abstract available.
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, Khorashad JS, Bua M, Alsuliman A, Khoder A, Stringaris K, Cooper N, Davis J, Goldman JM, Apperley JF, Rezvani K. Marin D, et al. Among authors: milojkovic d. Leukemia. 2012 Feb;26(2):296-302. doi: 10.1038/leu.2011.180. Epub 2011 Aug 16. Leukemia. 2012. PMID: 21844874
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Ibrahim AR, Clark RE, Holyoake TL, Byrne J, Shepherd P, Apperley JF, Milojkovic D, Szydlo R, Goldman J, Marin D. Ibrahim AR, et al. Among authors: milojkovic d. Haematologica. 2011 Dec;96(12):1779-82. doi: 10.3324/haematol.2011.049759. Epub 2011 Aug 22. Haematologica. 2011. PMID: 21859733 Free PMC article. Clinical Trial.
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D. Neelakantan P, et al. Among authors: milojkovic d. Haematologica. 2012 Sep;97(9):1444. doi: 10.3324/haematol.2012.064618. Epub 2012 Apr 24. Haematologica. 2012. PMID: 22532521 Free PMC article. No abstract available.
Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K. Innes AJ, et al. Among authors: milojkovic d. Bone Marrow Transplant. 2013 Oct;48(10):1324-8. doi: 10.1038/bmt.2013.69. Epub 2013 May 20. Bone Marrow Transplant. 2013. PMID: 23686098
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D. Neelakantan P, et al. Among authors: milojkovic d. Br J Haematol. 2014 Feb;164(4):608-10. doi: 10.1111/bjh.12648. Epub 2013 Nov 13. Br J Haematol. 2014. PMID: 24219400 Free article. No abstract available.
136 results